In today’s briefing:
- Lotus Pharmaceutical (1795 TT): Ready for Next Phase of Growth with New Ownership and Product Launch
Lotus Pharmaceutical (1795 TT): Ready for Next Phase of Growth with New Ownership and Product Launch
- Aztiq and Innobic have formally become the leading shareholder of Lotus Pharmaceutical (1795 TT), with the controlling stake of 51%. New ownership will accelerate the growth and expansion of Lotus.
- Lotus has created a niche for itself through its focus on oral oncology drug. Launch of Lenalidomide in 14 European countries drove 31% q/q growth in export revenue in Q1.
- Continued strong uptake of the company’s newly acquired drug Cialis in Taiwan and bevacizumab biosimilar launch in Korea and Taiwan should boost its Asian business revenue.
Related tickers: Lotus Pharmaceutical (1795.TWO)
Before it’s here, it’s on Smartkarma
